Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P36405

UPID:
ARL3_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P36405; B2R6C7; Q53X83; Q5JSM2

BACKGROUND:
The ADP-ribosylation factor-like protein 3 is crucial for normal cell division and the signaling mechanisms of cilia. It requires the assistance of GTPase-activating proteins to transition between its active and inactive forms. This protein's role in delivering key molecules like NPHP3 and INPP5E to the ciliary membrane underscores its importance in cellular function and signaling.

THERAPEUTIC SIGNIFICANCE:
The association of ADP-ribosylation factor-like protein 3 with diseases such as Joubert syndrome 35 and Retinitis pigmentosa 83 underscores its therapeutic potential. Exploring the mechanisms by which this protein influences disease pathology could lead to novel treatment options, emphasizing the importance of research into its biological functions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.